Mylan said on Tuesday it is issuing a nationwide voluntary recall of all lots of its blood pressure medicine valsartan, expanding a recall of select batches initiated two weeks ago.
The drugmaker said it was recalling 104 additional lots “out of an abundance of caution” after the valsartan-containing products were found to contain traces of a probable cancer-causing impurity.
The finished products, which were manufactured by Mylan Pharmaceuticals and Mylan Laboratories were distributed in the United States between March 2017 and November 2018, the company said in a statement.
Shares of the company fell 2 percent to $33.40 after the announcement.
